Previous 10 | Next 10 |
MOUNTAIN VIEW, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing on April 1, 2022 of its previously announced underwritten public offering of 8,695,653 shares of its non-voting common stock and, pursuant to the exercise in full by th...
3 Health Care Stocks For Your April 2022 List Health care stocks may not be the most exciting segment in the stock market . But they came to the fore over the past two years amid the pandemic. but it is often relatable among consumers. Far too often, people take health care for ...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
IGM Biosciences (NASDAQ:IGMS) has priced its underwritten public offering of ~8.7M shares of its non-voting common stock at a price to the public of $23.00/share for expected total gross proceeds of ~$200.0M. Underwriters over-allotment is an additional 1,304,347 shares of its voting common s...
MOUNTAIN VIEW, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its underwritten public offering of 8,695,653 shares of its non-voting common stock at a price to the public of $23.00 per share. IGM expects to receive total gross ...
The optimism on Wall Street continued during Tuesday's session, as the Nasdaq led the major U.S. equity indices higher yet again. As a result, the S&P 500 recorded its first close above 4,600 since mid-January. While the overall market pushed higher, in part on hopeful signs out of peace ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, a whirlwind of news surrounds IGM Biosciences (NASDAQ: IGMS ). It also happens to be very positive for IGMS stock; shares of the biotech company have more than doubled in rather impressive fashion. ...
Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...
Shares of IGM Biosciences (NASDAQ: IGMS) , a clinical-stage biotechnology company, were trading an astonishing 130% higher as of 11:30 a.m. ET Tuesday as investors responded to news that it had signed a significant collaboration deal with Sanofi (NASDAQ: SNY) . IGM Biosc...
IGM Biosciences (NASDAQ:IGMS +120.3%) stock soared following its Q4 results and announcing a collaboration with Sanofi (SNY) for oncology and autoimmune disorder programs potentially worth over $6B. The company's Q4 research and development expenses rose to $39.17M, compared to $19....
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...